Revelation Biosciences, Inc. REVB
We take great care to ensure that the data presented and summarized in this overview for REVELATION BIOSCIENCES, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding REVB
View allLatest Institutional Activity in REVB
Top Purchases
Top Sells
About REVB
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
Insider Transactions at REVB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 11
2025
|
Jennifer Carver |
BUY
Grant, award, or other acquisition
|
Direct |
181
+49.18%
|
$543
$3.87 P/Share
|
|
Feb 11
2025
|
Lakhmir S Chawla |
BUY
Grant, award, or other acquisition
|
Direct |
181
+50.0%
|
$543
$3.87 P/Share
|
|
Feb 11
2025
|
Chester Stanley Zygmont Iii Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
15,048
+49.95%
|
$45,144
$3.87 P/Share
|
|
Feb 11
2025
|
James Rolke Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,095
+49.97%
|
$90,285
$3.87 P/Share
|
|
Feb 11
2025
|
Jess Roper |
BUY
Grant, award, or other acquisition
|
Direct |
181
+49.73%
|
$543
$3.87 P/Share
|
|
Feb 11
2025
|
George F Tidmarsh |
BUY
Grant, award, or other acquisition
|
Indirect |
181
+40.31%
|
$543
$3.87 P/Share
|
|
Dec 08
2023
|
George F Tidmarsh |
SELL
Open market or private sale
|
Direct |
27,771
-100.0%
|
$0
$0.52 P/Share
|
|
Oct 16
2023
|
George F Tidmarsh |
SELL
Open market or private sale
|
Direct |
1,845
-6.23%
|
$0
$0.65 P/Share
|
|
Oct 16
2023
|
George F Tidmarsh |
SELL
Open market or private sale
|
Indirect |
10,957
-20.65%
|
$0
$0.66 P/Share
|
|
Sep 28
2023
|
George F Tidmarsh |
SELL
Open market or private sale
|
Indirect |
1,429
-3.28%
|
$0
$0.69 P/Share
|
|
Sep 18
2023
|
George F Tidmarsh |
SELL
Open market or private sale
|
Direct |
4,000
-9.23%
|
$0
$0.74 P/Share
|
|
Sep 15
2023
|
George F Tidmarsh |
SELL
Open market or private sale
|
Direct |
9,500
-17.98%
|
$0
$0.73 P/Share
|
|
Sep 14
2023
|
George F Tidmarsh |
SELL
Open market or private sale
|
Direct |
12,000
-18.5%
|
$0
$0.75 P/Share
|
|
Apr 18
2023
|
George F Tidmarsh |
BUY
Open market or private purchase
|
Direct |
25,000
+27.82%
|
$25,000
$1.16 P/Share
|
|
Apr 17
2023
|
George F Tidmarsh |
BUY
Open market or private purchase
|
Direct |
26,500
+39.94%
|
$26,500
$1.16 P/Share
|
|
Feb 25
2022
|
George F Tidmarsh |
BUY
Open market or private purchase
|
Direct |
20,000
+4.11%
|
$20,000
$1.6 P/Share
|
|
Feb 09
2022
|
George F Tidmarsh |
BUY
Open market or private purchase
|
Direct |
30,000
+6.29%
|
$60,000
$2.55 P/Share
|
|
Feb 08
2022
|
George F Tidmarsh |
BUY
Open market or private purchase
|
Direct |
1,000
+0.24%
|
$2,000
$2.54 P/Share
|
|
Feb 07
2022
|
George F Tidmarsh |
BUY
Open market or private purchase
|
Indirect |
42,100
+2.69%
|
$84,200
$2.61 P/Share
|
|
Feb 04
2022
|
George F Tidmarsh |
BUY
Open market or private purchase
|
Indirect |
7,900
+0.53%
|
$15,800
$2.31 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 45.9K shares |
|---|